| Australian Study Reveals New Mesothelioma Biomarker |
A large multi-center Australian study has revealed what researchers say could be an important new biomarker for malignant mesothelioma.
Mesothelioma is a virulent cancer of internal body membranes usually caused by exposure to asbestos. As with other cancers, mesothelioma cells produce certain compounds at higher levels than healthy cells do.
Micro RNAs, or miRNAs, are short chains of ribonucleic acid, some of which are produced in abundance by cancer cells. Using miRNA microarrays, the Australian researchers profiled plasma samples from patients with malignant mesothelioma and from healthy controls. After reviewing 90 miRNAs previously associated with mesothelioma, they found two – miR-29c and miR-92a – in particularly high amounts.
Further testing found a total of 15 novel miRNAs in the plasma of mesothelioma patients. Among them was miR-625-3p, a novel miRNA that was not only in significantly higher in concentration but could also be used to discriminate between the mesothelioma cases and the healthy plasma samples. In addition, miR-625-3p was found to be significantly higher in tumors removed from 18 mesothelioma patients who had undergone extrapleural pneumonectomy surgery.
"Our data… reveal that McR-624-3p is a promising novel diagnostic marker for malignant mesothelioma," conclude the researcher in the Journal of Thoracic Oncology. The finding could make it possible to identify mesothelioma with a simple blood test.
Biomarkers are especially important in mesothelioma, whose symptoms tend to mimic other respiratory illnesses until the disease is in its advanced stages. MiRNAs are not the only biomarkers used to identify mesothelioma. Chemicals and proteins including serum mesothelin, osteopontin and an enzyme called MTAP are all being explored for their potential to pinpoint mesothelioma earlier.
As many as 2,500 people are diagnosed with mesothelioma each year in the U.S. Many more contract the disease in underdeveloped countries where the use of asbestos is often poorly regulated.
Sources:
Kirschner, MB et al, "Increased circulating miR-625-3p: A Potential Biomarker for Patients with Malignant Pleural mesothelioma", May 21, 2012, Journal of Thoracic Oncology, Epub ahead of print.
© Surviving Mesothelioma and Cancer Monthly. All rights reserved.
DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.
